<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0002861'>Melanoma</z:hpo> antigen D1 (MAGED1) is a member of the type II <z:hpo ids='HP_0002861'>melanoma</z:hpo> antigen (MAGE) family </plain></SENT>
<SENT sid="1" pm="."><plain>The down-regulation of MAGED1 expression has been shown in <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> cell lines and in <z:hpo ids='HP_0009733'>glioma</z:hpo> stem cells and may play an important role in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and anti-<z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>However, there is no report on its clinical role in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We examined the expression of MAGED1 by qPCR in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues and their adjacent non-tumorous tissues taken from 6 cases and performed Western blotting and IHC analyses </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, we analyzed MAGED1 expression in 285 clinicopathologically characterized <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: MAGED1 expression was significantly down-regulated in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues compared with adjacent non-tumorous tissues and was associated with clinical stage (p &lt; 0.001), T classification (p = 0.001), N classification (p &lt; 0.001), M classification (p &lt; 0.001) and pathologic differentiation (p = 0.002) </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with lower MAGED1 expression had a shorter survival time than those with higher MAGED1 expression </plain></SENT>
<SENT sid="7" pm="."><plain>Univariate and multivariate analyses indicated that MAGED1 expression was an independent prognostic factors (p &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: MAGED1 may serve as a novel prognostic biomarker of human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>